Plus Gross Profit from 2010 to 2025

PSTV Stock

USD 0.73 0.05 7.35%

Plus Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Plus Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2001-03-31

Previous Quarter

1.5 M

Current Value

-1.5 M

Quarterly Volatility

43.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.

Check out the analysis of Plus Therapeutics Correlation against competitors.

For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Latest Plus Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Plus Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Plus Therapeutics minus its cost of goods sold. It is profit before Plus Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Plus Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (5.46 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Plus Gross Profit Regression Statistics

	Arithmetic Mean	2,544,210
	Geometric Mean	2,856,960
	Coefficient Of Variation	199.70
	Mean Deviation	4,314,316
	Median	1,835,000
	Standard Deviation	5,080,739
	Sample Variance	25.8T
	Range	15.3M
	R-Value	(0.79)
	Mean Square Error	10.2T
	R-Squared	0.63
	Significance	0.0002
	Slope	(846,801)
	Total Sum of Squares	387.2T

Plus Gross Profit History

	2025	-4.1 M
	2024	-4.3 M
	2023	-4.8 M
	2022	-488 K
	2021	-66 K
	2020	-2.4 M
	2019	1.6 M

Other Fundumenentals of Plus Therapeutics

Gross Profit Margin

Plus Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Retained Earnings	Net Receivables	Short Term Debt	Common Stock	Current Deferred Revenue	Accounts Payable	Intangible Assets	Good Will	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.47	0.21	0.85	0.86	0.09	0.7	0.16	0.62	0.34	0.45	0.49	0.58	-0.2	0.51	0.56	-0.58	-0.25	0.69	-0.24	0.35
Total Stockholder Equity	0.47		-0.15	0.0	0.37	-0.05	0.09	0.05	0.33	0.19	0.21	0.18	0.28	0.38	0.0	0.05	-0.08	0.11	0.48	0.1	0.42
Net Debt	0.21	-0.15		0.26	-0.25	0.18	0.27	0.4	0.33	-0.37	-0.05	0.79	0.45	-0.44	0.18	0.28	-0.31	0.08	0.46	-0.68	-0.08
Total Liab	0.85	0.0	0.26		0.81	0.08	0.71	0.14	0.51	0.28	0.47	0.4	0.45	-0.4	0.52	0.55	-0.56	-0.29	0.43	-0.33	0.11
Total Current Assets	0.86	0.37	-0.25	0.81		0.05	0.65	-0.04	0.4	0.51	0.47	0.09	0.33	-0.08	0.48	0.47	-0.48	-0.35	0.39	0.04	0.28
Retained Earnings	0.09	-0.05	0.18	0.08	0.05		0.45	-0.3	0.19	0.48	-0.81	0.46	0.73	-0.2	0.79	0.81	-0.8	-0.55	0.6	-0.42	0.12
Net Receivables	0.7	0.09	0.27	0.71	0.65	0.45		0.0	0.37	0.23	0.06	0.55	0.61	-0.24	0.79	0.79	-0.78	-0.59	0.58	-0.33	0.1
Short Term Debt	0.16	0.05	0.4	0.14	-0.04	-0.3	0.0		-0.14	-0.29	0.35	0.21	-0.09	-0.41	-0.4	-0.31	0.17	0.63	0.08	-0.33	-0.22
Common Stock	0.62	0.33	0.33	0.51	0.4	0.19	0.37	-0.14		0.04	0.14	0.61	0.6	0.17	0.49	0.54	-0.47	-0.15	0.59	-0.29	0.29
Current Deferred Revenue	0.34	0.19	-0.37	0.28	0.51	0.48	0.23	-0.29	0.04		-0.19	-0.2	0.33	-0.05	0.46	0.45	-0.45	-0.37	0.28	-0.17	0.08
Accounts Payable	0.45	0.21	-0.05	0.47	0.47	-0.81	0.06	0.35	0.14	-0.19		-0.18	-0.35	0.05	-0.38	-0.37	0.37	0.3	-0.23	0.14	-0.06
Intangible Assets	0.49	0.18	0.79	0.4	0.09	0.46	0.55	0.21	0.61	-0.2	-0.18		0.8	-0.3	0.54	0.64	-0.64	-0.21	0.8	-0.6	0.25
Good Will	0.58	0.28	0.45	0.45	0.33	0.73	0.61	-0.09	0.6	0.33	-0.35	0.8		-0.33	0.79	0.86	-0.84	-0.42	0.88	-0.54	0.25
Net Tangible Assets	-0.2	0.38	-0.44	-0.4	-0.08	-0.2	-0.24	-0.41	0.17	-0.05	0.05	-0.3	-0.33		-0.19	-0.22	0.32	0.06	-0.26	0.34	0.09
Long Term Debt	0.51	0.0	0.18	0.52	0.48	0.79	0.79	-0.4	0.49	0.46	-0.38	0.54	0.79	-0.19		0.99	-0.92	-0.8	0.67	-0.34	0.18
Long Term Debt Total	0.56	0.05	0.28	0.55	0.47	0.81	0.79	-0.31	0.54	0.45	-0.37	0.64	0.86	-0.22	0.99		-0.95	-0.74	0.75	-0.46	0.21
Capital Surpluse	-0.58	-0.08	-0.31	-0.56	-0.48	-0.8	-0.78	0.17	-0.47	-0.45	0.37	-0.64	-0.84	0.32	-0.92	-0.95		0.62	-0.79	0.44	-0.25
Property Plant Equipment	-0.25	0.11	0.08	-0.29	-0.35	-0.55	-0.59	0.63	-0.15	-0.37	0.3	-0.21	-0.42	0.06	-0.8	-0.74	0.62		-0.29	0.1	-0.2
Net Invested Capital	0.69	0.48	0.46	0.43	0.39	0.6	0.58	0.08	0.59	0.28	-0.23	0.8	0.88	-0.26	0.67	0.75	-0.79	-0.29		-0.37	0.44
Net Working Capital	-0.24	0.1	-0.68	-0.33	0.04	-0.42	-0.33	-0.33	-0.29	-0.17	0.14	-0.6	-0.54	0.34	-0.34	-0.46	0.44	0.1	-0.37		0.25
Capital Stock	0.35	0.42	-0.08	0.11	0.28	0.12	0.1	-0.22	0.29	0.08	-0.06	0.25	0.25	0.09	0.18	0.21	-0.25	-0.2	0.44	0.25

Click cells to compare fundamentals

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-4.3 M	-4.1 M
Gross Profit Margin	(1.12)	(1.06)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC